Skip to main content

Table 4 FDA approved biosimilars

From: Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa region

Date of biosimilar FDA approval Biosimilar product Original product Active substance
06 March 2015 (U.S. Department of Health and Human Services and Food and Drug Administration 2016a) Zarxio Neupogen Filgrastim
05 April 2016 (U.S. Department of Health and Human Services and Food and Drug Administration 2016b) Inflectra Remicade Infliximab
30 August 2016 (U.S. Department of Health and Human Services and Food and Drug Administration 2016c) Erelzi Enbrel Etanercept
23 September 2016 (U.S. Department of Health and Human Services and Food and Drug Administration 2016d) Amjevita Humira Adalimumab